Currently, there are no validated methods to assess the metabolic effects of Endocrine Disruptors (EDs). To address this unmet need and other gaps in the context of ED testing, the European Union has funded eight projects on the overarching topic ‘New testing and screening methods to identify endocrine disrupting chemicals’ within the Horizon 2020 framework. One of these projects is EDCMET.


Projektin tiedot

Projektin kesto



Horisontti 2020

Projektin koordinaattori

University of Eastern Finland

Projektin kuvaus

EDCMET - ‘Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways’. The objective of the project is to develop validated in silico, in vitro and in vivo methods assessing metabolic effects of EDs, with a focus on energy and fat metabolism and nuclear receptors regulating these processes. Thorough understanding of the mechanisms leading to adverse metabolic effects of EDs is presently lacking.

EDCMET will apply the adverse outcome pathway (AOP) paradigm to identify molecular initiating events and predict the emergent adverse biological phenotype. The project brings together scientists with different expertise to meet the common goal to improve the currently available testing methods. EDCMET utilizes a wide variety of methodologies, ranging from computational methods, cell culture systems and up-to-date animal models, to epidemiological data, in order to associate the exposure to chemicals to ED-related metabolic effects.

UOulu group consists of three researcher groups, Prof. Jukka Hakkola, Prof. Arja Rautio and Prof. Marjo-Riitta Järvelin, from the Faculty of Medicine.

For more information about EDCMET project, please visit the EDCMET website.